Please assess the completion status of the following clinical trial:

Trial Title: Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Each patient must meet all of the following inclusion criteria to be enrolled in the study:~1. Diagnosis of moderately to severely active ulcerative colitis~2. Demonstrated, over the previous 5 year period, an inadequate response to, loss of response to, or intolerance at least 1 of the following agents:~   1. Immunomodulators~  2. Tumor necrosis factor-alpha (TNFα) antagonists~  3. Corticosteroids~3. May be receiving a therapeutic dose of conventional therapies for inflammatory bowel disease (IBD) as defined by the protocol~Exclusion Criteria:~1. Evidence of abdominal abscess at the initial screening visit~2. Extensive colonic resection, subtotal or total colectomy~3. Ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine~4. Have received non permitted IBD therapies within either 30 or 60 days, depending on the medication, as stated in the protocol~5. Chronic hepatitis B or C infection~6. Active or latent tuberculosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Vedolizumab (Type: EXPERIMENTAL): In the Induction Phase participants received vedolizumab 300 mg, administered by intravenous infusion at Week 0 and Week 2 (Days 1 and 15).~In the Maintenance Phase, participants who demonstrated a clinical response at Week 6 according to protocol-specified criteria were randomized in a 1:1:1 ratio to double-blind treatment with vedolizumab administered every 4 weeks, vedolizumab administered every 8 weeks, or placebo for up to Week 50. Participants who did not demonstrate response at Week 6 of the Induction Phase continued treatment with vedolizumab, administered every 4 weeks during the Maintenance Phase.
- Placebo (Type: PLACEBO_COMPARATOR): In the Induction Phase participants received placebo intravenous infusion at Week 0 and Week 2 (Days 1 and 15). Participants continued to receive placebo during the Maintenance Phase, regardless of treatment response during Induction.

Based on this trial design, predict the completion outcome and termination type (if applicable).